Advanced FMD Subunit Vaccine Description
This quadrivalent vaccine is developed using advanced la tecnologia delle particelle simili a virus (VLP), representing the next generation of foot-and-mouth disease (FMD) vaccines.
Unlike traditional inactivated vaccines, this product contains non-infectious VLP antigens, which structurally mimic the native virus but contain no viral genetic material. This ensures excellent safety with zero risk of viral replication or reversion, while maintaining strong immunogenicity.
The vaccine provides protection against four major FMD serotypes of global importance:
- Sierotipo O (linea PanAsia2)
- Sierotipo A (linea Iran05)
- Type Asia 1
- Type SAT 2
These serotypes are responsible for most transboundary FMD outbreaks across Asia, the Middle East, and Africa. The inclusion of SAT 2 significantly enhances protection for regions with emerging or complex epidemiological risks.
Immunity develops within 3 weeks after vaccination and lasts for up to 6 months, making this vaccine suitable for both routine immunization and strategic disease control programs, including high-biosecurity farms and international livestock trade systems.
Programma di immunizzazione
- Calves:
- First dose: at approximately 90 days of age (2.0 mL)
- Booster: 30 days later
- Routine Revaccination:
- Every 4–6 months
- Ovini:
- Half dose of cattle regimen
Dosaggio e somministrazione
- Route: Intramuscular injection
- Bovini: 2.0 mL per dose
- Ovini: 1.0 mL per dose
Antigen Composition (VLP Content)
Ogni dose contiene:
- Type O (O/Tur/5/2009, PanAsia2): 52.5 μg VLP protein
- Type A (A/Tur/06-20, Iran05): 52.5 μg VLP protein
- Type Asia 1 (Asia 1/Pak/08): 52.5 μg VLP protein
- Type SAT 2 (Eritrea 98, XIV): 52.5 μg VLP protein
Caratteristiche del prodotto
- Appearance: Milky-white emulsion
- Non-infectious VLP formulation
- High antigen purity and stability
Safety & Adverse Reactions
General safety profile:
- Typically no significant adverse reactions
Possibili reazioni lievi:
- Gonfiore nel sito di iniezione
- Febbre temporanea
- Riduzione dell'ingestione di mangime (1–2 giorni)
Questi effetti si risolvono solitamente entro 3–5 giorni.
Rare reazioni gravi:
- Ipersensibilità:
- Irrequietezza
- Respirazione rapida
- Tremori muscolari
- Congestione delle mucose
- In rari casi:
- Morte se non trattata
- Possibile aborto negli animali gravidi
Gestione dell'emergenza:
- Somministrazione immediata di epinefrina
- Cure veterinarie di supporto
Confezionamento e specifiche
- Specifiche: 100 ml/flacone
- Confezionamento: 100 flaconi/cartone
Conservazione e durata di conservazione
- Conservazione: 2–8°C
- Proteggere dalla luce
- NON congelare
- Durata: 24 mesi
Precauzioni
- Usare solo in animali da allevamento sani
- Avoid vaccination in:
- Gravidanza iniziale e tardiva
- Pre-weaning animals
- Animals under transport stress
- Portare il vaccino a temperatura ambiente e agitare bene prima dell'uso
- Use opened vaccine within the same day
- Follow strict aseptic procedures:
- Disinfect injection sites
- Use sterile equipment
- Replace needles between animals
- Vaccination should be performed by trained professionals
- In outbreak control:
- Vaccinate in order: safe area → threatened area → epidemic area
- Movement restriction:
- Allow livestock movement only after 21 days post-vaccination in non-epidemic areas
- Combine vaccination with:
- Biosicurezza
- Quarantine
- Disinfection protocols
